Category: 02 – February
-
REGENXBIO Inc. v. Sarepta Therapeutics, Inc.
A biological composition is patent‑eligible when the claimed construct, viewed as a whole, does not occur in nature and exhibits characteristics or utility that differ meaningfully from its natural components.
-
Genuine Enabling Technology LLC v. Sony Group Corporation
A patent owner fails to meet its burden of proving structural equivalence when it does not address a significant part of the structure identified in the specification as the corresponding means‑plus‑function element.
-
Willis Electric Co., Ltd. v. Polygroup Ltd. (Macao Commercial Offshore)
When a damages expert employs a facially reliable apportionment methodology grounded in evidence and tied to the claimed invention’s incremental value, challenges to data selection, assumptions, or modeling choices ordinarily go to weight, not admissibility.
-
Apple Inc. v. Squires
The Director’s instructions to the PTAB regarding institution of IPRs are not subject to formal notice-and-comment rulemaking since these instructions constitute general statements of policy rather than substantive rules.
-
Netflix, Inc. v. DivX, LLC
A modifying phrase is presumed to attach to the nearest semantically plausible term, but that presumption can be overcome if the claim language, specification, or prosecution history indicates a contrary interpretation.